Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders.

Veit, J G S; Poumay, Y; Mendes, D; Kreitinger, J; Walker, L; Paquet, A; Menigot, C; Zolezzi, F; Paller, A S; Diaz, P

Veit, J G S; Poumay, Y; Mendes, D; Kreitinger, J; Walker, L; Paquet, A; Menigot, C; Zolezzi, F; Paller, A S; Diaz, P.

Afiliação

Veit JGS; Department of Biomedical and Pharmaceutical Sciences University of Montana Missoula Montana USA.
Poumay Y; URPHYM-NARILIS University of Namur Namur Belgium.
Mendes D; R&D DermaXon LLC Missoula Montana USA.
Kreitinger J; URPHYM-NARILIS University of Namur Namur Belgium.
Walker L; R&D DermaXon LLC Missoula Montana USA.
Paquet A; R&D DermaXon LLC Missoula Montana USA.
Menigot C; R&D DermaXon LLC Missoula Montana USA.
Zolezzi F; Syneos Health Biot France.
Paller AS; Syneos Health Biot France.
Diaz P; Syneos Health Biot France.

Skin Health Dis ; 1(2): e22, 2021 Jun.

Article em En | MEDLINE | ID: mdl-35664983

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Skin Health Dis Ano de publicação: 2021 Tipo de documento: Article